Protalix BioTherapeutics Sees Large Increase in Short Interest (PLX)
Shares of Protalix BioTherapeutics (NYSE:PLX) were the target of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 5,944,336 shares, a growth of 0.4% from the July 31st total of 5,921,103 shares, Stock Ratings Network.com reports. Based on an average daily volume of 408,537 shares, the days-to-cover ratio is currently 14.6 days. Approximately 7.7% of the shares of the company are sold short.
Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, August 11th. They now have a $3.50 price target on the stock, down previously from $4.25.
Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 2.61 on Friday. Protalix BioTherapeutics has a 52-week low of $2.35 and a 52-week high of $5.60. The stock has a 50-day moving average of $3.02 and a 200-day moving average of $3.95. The company’s market cap is $242.3 million.
Protalix BioTherapeutics (NYSE:PLX) last released its earnings data on Friday, August 15th. The company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.07). Analysts expect that Protalix BioTherapeutics will post $-0.21 EPS for the current fiscal year.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Receive News & Ratings for Protalix BioTherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.